Criminal Prosecution of UCB, Inc.
In June 2011, UCB, Inc. paid $34.4 million to resolve criminal and civil FCA liability arising from the illegal marketing of the epilepsy drug, Keppra, for off-label uses that were not medically accepted indications and ineligible for coverage, including headache, migraine, pain, bipolar, mood disorders, and anxiety. Under the terms of a separate criminal agreement, UCB pled guilty to one count of misdemeanor misbranding under the FDCA and paid an $8.6 million criminal fine.
Source: HHS Health Care Fraud and Abuse Control Program, Annual Report for FY 2011
This article was posted on July 15, 2012.